Leflunomide’s interaction with dopamine receptors (Table 4), is a potential avenue to help explain the PN, as dopamine transporters contribute to Parkinson’s disease (PD) [87] and PN is more prevalent in patients with PD [88]. This evidence concerns the gene SLC6A3 and Parkinson disease.